OACC · Oaktree Acquisition Corp. III Life Sciences
$10.72
-0.02 (-0.19%)
At close · Jul 29
Going-concern doubt
— flagged May 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Such potential liquidity shortfall and mandatory liquidation condition raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed May 13, 2026
Market Cap
$263.53M
Shares
24.58M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.72
Open$10.72
Day$10.72–10.72
52W$10.30–10.75
Avg vol 30d30K
Short int12K · 0.0% float · 1.4d
Short vol0%
DataDec 2024–Jul 2026
Filing10-Q · May 13
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very Low
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+1%
above
Price vs 50-day avg
+0%
above
RSI (14)
59
neutral
MACD trend
Positive
52-week position
93%
near high
Momentum
relative strength
1-month return
0%
trailing
6-month return
0%
trailing
YTD return
+1%
this year
Relative strength
−6%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $11 › 200d $11 — 50d above 200d
Institutional flow
Distributing
2 of 51 funds reported for Jun 30 · net -8.8K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.05% of float · ▼ -0.2% MoM · 1.4 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
51 holders — near 1-yr high, broad support
Squeeze score
41
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
5%
annualized · 1-yr
Max drawdown
−2%
past year
ATR
0.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+1%
Bullish
Price vs 50-day avg
+0%
Bullish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
93%
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $11 › 200d $11 — 50d above 200d
Institutional flow
Distributing
2 of 51 funds reported for Jun 30 · net -8.8K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.05% of float · ▼ -0.2% MoM · 1.4 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
51 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $10
Now $11 · 93%
52-wk high $11
vs 200-day avg +1%
vs 50-day avg +0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Shell Companies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OACC
this stock
Oaktree Acquisition Corp. III Life Sciences
|
$263.53M | +1.3% | — | — | 0.0% |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | +0.0% | — | 100.2 | — |
|
XXI
Twenty One Capital, Inc.
|
$2.87B | -50.3% | — | — | 0.7% |
|
CCXI
Churchill Capital Corp XI
|
$808.76M | — | — | — | 1.8% |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$644.64M | +2.2% | — | — | 0.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OACC | +0.1% | +0.2% | +0.3% | +0.2% | +1.3% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | +2.5% | +2.5% | -6.0% | +2.5% | -5.7% |